Answers are grounded in this paper and cite their sources.
Potential bias in ophthalmic pharmaceutical clinical trials Paul VarnerJohn J Pershing Veterans’ Administration Medical Center, Poplar Bluff, Missouri, USAAbstract: To make clinicians aware of potential sources of error in ophthalmic pharmaceutical clinical trials that can lead to erroneous interpretation of results, a critical review of the study design of various pharmaceutical ophthalmic clinical trials was completed. Discrepancies as a result of study shortcomings may explain observed differences between reported ophthalmic trial data and observed clinical results.
No takes yet. Share an insight, caveat, or question.
Paul Varner (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: